Company Encyclopedia
View More
name
MoonLake Immunotherapeutics
MLTX.US
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
1.902 T
MLTX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    11:21 ET MLTX DEADLINE: Faruqi & Faruqi Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX

    Faruqi & Faruqi, LLP is investigating potential claims against MoonLake (NASDAQ: MLTX) and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that MoonLake made false and/or misleading statements regarding its Nanobody structure's clinical benefits. Investors who suffered losses are encouraged to contact the firm to discuss their legal options.

    prnewswire·
    US
    MLTX
    +5.12%
    prnewswire·
    US
    MLTX
    +5.12%

    Berger Montague advises MoonLake Immunotherapeutics investors to contact the firm before Dec. 15, 2025 regarding a class action lawsuit against the company (MLTX) purchased during the period of March.

    A class action lawsuit has been filed by leading law firm Berger Montague PC against MoonLake Immunotherapeutics (NASDAQ: MLTX) on behalf of investors who bought the Company's shares between March and December 2025. The suit alleges misconduct causing financial harm to shareholders. Details of the case include specific dates and actions taken by MoonLake.

    Unusual Whales·
    US
    MLTX
    +5.12%
    Unusual Whales·
    US
    MLTX
    +5.12%

    07:36 ET MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

    The Schall Law Firm has announced a class action lawsuit against MoonLake Immunotherapeutics for securities fraud, alleging false and misleading statements about its drug candidate, sonelokimab. Investors who purchased shares between March 10, 2024, and September 29, 2025, are encouraged to join the lawsuit by December 15, 2025. The lawsuit claims MoonLake's public statements were misleading, leading to significant investor losses.

    prnewswire·
    US
    MLTX
    +5.12%
    prnewswire·
    US
    MLTX
    +5.12%

    Officer Reich Surrenders 202,908 Of MoonLake Immunotherapeutics [MLTX]

    Officer Kristian Reich of MoonLake Immunotherapeutics surrendered 202,908 shares valued at $3,012,453 to cover option exercise costs and tax liabilities. The transaction was disclosed in a Form 4 filed with the SEC. Reich's ending holdings are 2,974,551 shares, all held indirectly.

    Reuters·
    US
    MLTX
    +5.12%
    Reuters·
    US
    MLTX
    +5.12%

    Moonlake Immunotherapeutics Chief Scientific Officer Kristian Reich Reports Sale of Common Shares

    Kristian Reich, Chief Scientific Officer of Moonlake Immunotherapeutics, reported the sale of common shares of the company. This event was disclosed via EDGAR by the U.S. SEC. The information is for informational purposes and not financial advice.

    Reuters·
    US
    MLTX
    +5.12%
    Reuters·
    US
    MLTX
    +5.12%
    © 2025 Longbridge｜Disclaimer